Medication
Rybelsus is oral semaglutide for Type 2 diabetes. Convenient pill form, but strict dosing requirements (fasting, water only) and lower bioavailability than injectable.
| Generic name | semaglutide (oral) |
| Brand manufacturer | Novo Nordisk |
| FDA indication | Type 2 diabetes |
| FDA approval year | 2019 |
| Form | Oral tablet |
| Schedule | Daily, fasting |
| List price (cash) | $998/month |
For drug-class comparisons, see our medication-comparison hub:
Coverage varies significantly by carrier and employer plan. See our insurance hub for plan-specific guidance:
Rybelsus is the brand name for semaglutide (oral), manufactured by Novo Nordisk. Rybelsus is oral semaglutide for Type 2 diabetes. Convenient pill form, but strict dosing requirements (fasting, water only) and lower bioavailability than injectable.
Rybelsus list price is approximately $998/month. Insurance may cover it with prior authorization for FDA-approved indications.
FDA-approved 2019. Indication: Type 2 diabetes.
Doses available: 3 mg, 7 mg, 14 mg. Schedule: Daily, fasting. Always follow your prescribing clinician's titration plan.
See our medication comparisons hub for head-to-head pages on Wegovy vs Zepbound, Ozempic vs Wegovy, and semaglutide vs tirzepatide.
Note: This page is an editorial overview, not medical advice. Always consult a licensed clinician about whether Rybelsus is appropriate for you.